Clinical trial NCT05970471: Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital
Official title: Preferences of Patients Treated With Oral Cancer Drugs and Informal Caregivers for Pharmaceutical Consultation in Hospital: Discrete Choice Method to Inform Decision-making by Healthcare Professionals
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Preference, Patient
Pharmacist-Patient Relations
Caregiver
Cancer
Keywords: Preference, Patient
Pharmacist-Patient Relations
Cancer of Colon
Cancer, Breast
Lung Cancer
Prostate Cancer
Renal Cancer
caregiver
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2023-08-01
Enrollment: 240
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 240 patients - 60 Caregivers - 360 healhcare professionnals (pharmacist, oncologists, general practitioners)

Brief summary: To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to know who to refer to in case of a serious adverse effect, perform a pharmaceutical analysis of the prescription, and participate in the improvement and evaluation of overall compliance. OPCs are conditioned by the needs, expectations, and involvement of the patients in their care. In healthcare, patients are increasingly encouraged to play an active role in the knowledge and management of their health, express their concerns and preferences, and participate in medical decisions. Thus, it is essential to elicit their preferences. The discrete-choice experiment (DCE) is the validated and recommended method of the International Society for Pharmacoeconomics and Outcomes Research for such a task.

Detailed description: To ensure the safe use of oral anticancer drugs, oncology pharmacy consultations (OPCs) have been established in France. Their goal is to provide the patient with the means to identify, prevent and limit adverse effects and to know who to refer to in case of a serious adverse effect, perform a pharmaceutical analysis of the prescription, and participate in the improvement and evaluation of overall compliance. OPCs are conditioned by the needs, expectations, and involvement of the patients in their care. In healthcare, patients are increasingly encouraged to play an active role in the knowledge and management of their health, express their concerns and preferences, and participate in medical decisions. Thus, it is essential to elicit their preferences. The discrete-choice experiment (DCE) is the validated and recommended method of the International Society for Pharmacoeconomics and Outcomes Research for such a task.

Eligibility criteria: of patients:

Main inclusion Criteria:

* Patients with lung, prostate breast, prostate or renal cancer;
* Patients with oral cancer drugs;
* Patients accepted to take par in pharmaceutical consultation in hospital.

Primary outcomes:
measure: Preferences of patients
timeFrame: 12 months
Secondary outcomes:
measure: Preferences of cargivers and healthcare profesionnals
timeFrame: 12 months
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de Besançon
Study officials:
affiliation: CHU de Besançon
name: Virginie NERICH, PhD
role: PRINCIPAL_INVESTIGATOR
References: